Levodopa/carbidopa continuous-release - SynAgile

Drug Profile

Levodopa/carbidopa continuous-release - SynAgile

Alternative Names: Carbidopa/levodopa - SynAgile; Carbidopa/levodopa continuous-release - SynAgile; DopaFuse; L-DOPA/carbidopa continuous-release - SynAgile

Latest Information Update: 02 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SynAgile Corporation
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 08 Oct 2015 Phase-II clinical trials in Parkinson's disease in Italy (PO) before October 2015
  • 08 Oct 2015 Efficacy and adverse events data from a phase IIa trial in Parkinson's disease released by SynAgile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top